Liquidia Corp Files 8-K for Other Events and Exhibits

Ticker: LQDA · Form: 8-K · Filed: Sep 17, 2024

Sentiment: neutral

Topics: 8-K, filing, regulatory

TL;DR

Liquidia filed an 8-K, likely with important updates. Check for details.

AI Summary

On September 16, 2024, Liquidia Corporation filed an 8-K report to disclose other events and financial statements/exhibits. The filing does not detail specific transactions or financial figures but serves as a notification of these filings.

Why It Matters

This filing indicates that Liquidia Corporation is providing updates or supplementary information to the SEC, which could include important operational or financial disclosures.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain immediate negative or positive financial news.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Liquidia Corporation in this 8-K filing?

The filing itself does not specify the 'Other Events' but indicates that this item is being reported under the 8-K form.

What types of financial statements and exhibits are included with this 8-K filing?

The filing states that 'Financial Statements and Exhibits' are being provided, but the specific contents are not detailed in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported is dated September 16, 2024.

What is Liquidia Corporation's principal executive office address?

Liquidia Corporation's principal executive offices are located at 419 Davis Drive, Suite 100, Morrisville, North Carolina 27560.

What is the Commission File Number for Liquidia Corporation?

Liquidia Corporation's Commission File Number is 001-39724.

Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-09-17 17:15:21

Filing Documents

01 Other Events

Item 8.01 Other Events. As previously disclosed, on August 21, 2024, Liquidia Corporation, a Delaware corporation (the "Company") filed a lawsuit (the "FDA Suit") in the U.S. District Court of the District of Columbia (the "District Court") (Case No. 1:24-cv-02428) that challenged the recent decision by the U.S. Food and Drug Administration (the "FDA") to grant 3-year new clinical investigation exclusivity (NCI exclusivity) to Tyvaso DPI. As also previously disclosed, on August 20, 2024, United Therapeutics Corporation ("United Therapeutics") voluntarily dismissed, without prejudice, the complaint it had filed against the FDA in the District Court, challenging the FDA's acceptance of Liquidia's amended New Drug Application (the "NDA") for YUTREPIA (treprostinil) inhalation powder ("YUTREPIA") for review. On September 16, 2024, United Therapeutics filed new cross-claims in the FDA Suit against the FDA, re-asserting its challenge to the FDA's acceptance of Liquidia's NDA for YUTREPIA. The Company intends to vigorously defend its ability to launch YUTREPIA and to defend itself against these allegations.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. September 17, 2024 Liquidia Corporation By: /s/ Michael Kaseta Name: Michael Kaseta Title: Chief Financial Officer and Chief Operating Officer

View on Read The Filing